NuThrax (Cyfendus™)
Post-Exposure Prophylaxis of Anthrax
Key Facts
About Emergent BioSolutions
Emergent BioSolutions' mission is to protect and enhance life by providing preparedness and response solutions for public health threats. Its core achievement is establishing itself as a primary supplier of anthrax and smallpox countermeasures to the U.S. Strategic National Stockpile, supported by deep regulatory expertise and large-scale manufacturing capabilities. The company's strategy is dual-pronged: securing and expanding government procurement contracts for its biodefense portfolio while leveraging its CDMO services for external commercial clients. However, its recent financial and operational challenges, including significant debt and manufacturing setbacks, have pressured its valuation and strategic execution.
View full company profileTherapeutic Areas
Other Post-Exposure Prophylaxis of Anthrax Drugs
| Drug | Company | Phase |
|---|---|---|
| AV7909 | Emergent BioSolutions | BLA Submitted |
| Anthrax Vaccine Adsorbed (BioThrax®) | Emergent BioSolutions | Marketed |